ArticleNeurochemical research2026
Octreotide Attenuates Anxiety-Like Behaviors and Cognitive Deficits in a Rat Model of Post-traumatic Stress Disorder.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-traumatic stress disorder (PTSD) is a long-lasting mental health condition characterized by persistent intrusive recollections, avoidance behaviors, mood and cognitive alterations, heightened arousal, and significant cognitive deficits, often accompanied by hypothalamic-pituitary-adrenal (HPA) axis dysregulation and neuroinflammation. This study evaluated the therapeutic potential of octreotide (OCT), a synthetic somatostatin analog, in a rat model of PTSD induced by foot-shock contextual fear conditioning. Male Wistar rats (n = 40) were randomly assigned to four groups (n = 10/group): Saline/No Stress (control), OCT/No Stress (drug alone), Saline/PTSD (model + saline), and OCT/PTSD (model + OCT). OCT was administered intraperitoneally at 50 µg/kg daily for 21 days post-induction. Behavioral outcomes were assessed using the Open Field Test (anxiety-like exploration and locomotor activity), Elevated Zero Maze (anxiety-like avoidance), and Morris Water Maze (spatial learning and memory). Plasma corticosterone concentrations were recorded on Days 0, 1, 7, 14, and 21. Hippocampal TNF-α, superoxide dismutase (SOD) activity, and malondialdehyde levels were quantified post-behavioral testing via ELISA. The Saline/PTSD group displayed significantly elevated plasma corticosterone (P < 0.0001 from Day 1 onward), increased hippocampal TNF-α (P < 0.0001), decreased SOD activity (P < 0.0001), elevated MDA (P < 0.0001), reduced locomotor activity and central exploration in the Open Field Test (P < 0.0001 to P < 0.01), and impaired spatial memory retention in the Morris Water Maze probe trial (P < 0.0001). The Elevated Zero Maze did not reveal any significant differences. OCT treatment in the OCT/PTSD group significantly attenuated these alterations compared to the Saline/PTSD group, normalizing corticosterone from Day 7 onward, reducing TNF-α and MDA (P < 0.0001), restoring SOD activity (P < 0.01), and improving Open Field exploration and Morris Water Maze probe performance (P < 0.01). These findings demonstrate that OCT is associated with neuroprotective, anti-inflammatory, and antioxidant effects in a PTSD model, attenuating HPA hyperactivity, neuroinflammation, oxidative stress, and behavioral/cognitive deficits (though direct SSTR-mediated mechanisms remain to be experimentally confirmed). Given its established safety profile and clinical approval for other indications, OCT represents a promising candidate for repurposing in PTSD treatment.
Indexed as
Identifiers
42501137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.